Vorinostat (Zolinza; SAHA; CAS 149647-78-9): NIOSH HD Category 1 FORTY-SEVENTH Mechanism Class [FIRST PAN-HDAC INHIBITOR EVER FDA APPROVED (NDA 021743; October 6, 2006; HDAC1 IC50 ∼10 nM; HDAC6 IC50 ∼11 nM; Suberoylanilide Hydroxamic Acid; MW ∼264.3 g/mol; Hydroxamic Acid Zn2+ Bidentate Chelation Classes I/IIb/IV)] + FIRST EPIGENETIC ENZYME ANTICANCER DRUG EVER + Victoria Richon/Paul Marks Columbia–MSK 18-Year Discovery + Merck Aton Pharma $85M 2004 + CTCL ORR 24.2% (DOR 168 Days); Merck MSD Whitehouse Station NJ Cority ÷10; Merck Manufacturing Barceloneta PR VelocityEHS ÷10; Memorial Sloan Kettering New York NY EHS Insight ÷10; Glyphward Threshold 22; 607th Adversarial Attack; 137th Long-Form Blog

Vorinostat (Zolinza®; suberoylanilide hydroxamic acid; SAHA; CAS 149647-78-9; MW ∼264.3 g/mol; C14H20N2O3; linear octanediamide-anilide-hydroxamate scaffold [N-hydroxy-N′-phenyloctanediamide: phenyl ring + six-methylene suberoyl chain + hydroxamic acid terminus]; NIOSH HD Category 1; Merck Sharp & Dohme Corp NDA 021743 October 6, 2006; MECHANISM: FORTY-SEVENTH MECHANISM CLASS in the 607-ATTACK GLYPHWARD ADVERSARIAL PORTFOLIO — HISTONE DEACETYLASE (HDAC) INHIBITOR; THE FIRST PAN-HDAC INHIBITOR EVER FDA APPROVED IN ANY INDICATION, WORLDWIDE; HISTORICAL PRECEDENCE: vorinostat was approved in 2006 when no HDAC inhibitor had ever been approved by any regulatory agency; romidepsin (attack #608) followed in 2009; belinostat (attack #609) in 2014; panobinostat (attack #610; voluntary market withdrawal April 2022) in 2015; the HDAC inhibitor class that vorinostat founded encompasses four FDA approvals across two indications; THE FIRST EPIGENETIC ENZYME ANTICANCER DRUG EVER: vorinostat targets histone deacetylase enzymes — epigenetic regulatory proteins that remove acetyl groups from histone lysine residues, controlling chromatin accessibility and gene expression; no drug had previously targeted an epigenetic enzyme for cancer treatment; IDH1 (enasidenib; 2017), IDH2 (ivosidenib; 2018), and EZH2 methyltransferase (tazemetostat; 2020; Class 11 in Glyphward portfolio) followed years later; October 6, 2006 marks the moment the FDA oncology approval canon expanded from signal transduction pharmacology and DNA damage repair into chromatin biology and epigenetic gene regulation; HYDROXAMIC ACID Zn2+ BIDENTATE CHELATION: SAHA’s hydroxamic acid C=O oxygen and N-OH oxygen coordinate the catalytic Zn2+ ion in the HDAC active site in bidentate geometry, displacing catalytic water and blocking deacetylase activity across all zinc-dependent HDAC isoforms (Class I: HDAC1 IC50 ∼10 nM, HDAC2 ∼10 nM, HDAC3 ∼20 nM, HDAC8 ∼28 nM; Class IIa: HDAC4/5/7/9 ∼100–300 nM; Class IIb: HDAC6 IC50 ∼11 nM, HDAC10; Class IV: HDAC11); Class III sirtuins (SIRT1–7; NAD+-dependent deacylases; no Zn2+) NOT inhibited; BIOLOGICAL CONSEQUENCES: histone H3/H4 hyperacetylation → p21/CDKN1A re-expression (G1 arrest) + p16/CDKN2A + pro-apoptotic gene induction; HDAC6 inhibition → α-tubulin and Hsp90 hyperacetylation + aggresome pathway disruption; ALL ABSENT FROM EHS DATABASES; CTCL: NDA 021743 cutaneous T-cell lymphoma (CTCL) ≥2 prior systemic therapies; NCT00094783 n=74; ORR 24.2%; DOR 168 days; pruritus improvement 32%; H340 H350 H360 absent all three platforms; DISCOVERY: Victoria Richon PhD (Columbia/MSK) + Paul Marks MD (President MSK) + Ronald Breslow PhD (Columbia Chemistry); HPC program 1988–2001; Aton Pharma 2001; Merck $85M 2004; 18-year arc; OSHA: No PEL; ACGIH: No TLV; NIOSH: No REL; GHS H340 H350 H360; 607th adversarial attack; 137th long-form blog).

FORTY-SEVENTH MECHANISM CLASS: Histone Deacetylase Enzymes and the Opening of the Epigenetic Enzyme Era in Oncology

The forty-six prior mechanism classes in the Glyphward adversarial portfolio trace the complete arc of signal transduction and DNA repair oncology pharmacology: BCR-ABL tyrosine kinase (imatinib; Class 1; 2001), EGFR (Classes 32+; gefitinib through osimertinib), CDK4/6 (palbociclib; Class 33), BTK (ibrutinib; Class 29), PI3Kδ (idelalisib; Class 40; attack #592; 134th blog at glyphward.com), PH-domain allosteric AKT (capivasertib; Class 41; attack #596; 135th blog at glyphward.com), next-generation AR signaling (enzalutamide; Class 45; attack #602), PARP1/2 DNA damage repair enzyme (olaparib; Class 46; attack #605; 136th blog at glyphward.com), and EZH2 histone methyltransferase (tazemetostat; Class 11; attack #521; 119th blog). Class 46 (olaparib) introduced DNA repair enzyme pharmacology. The FORTY-SEVENTH mechanism class — vorinostat and the HDAC inhibitors — introduces the epigenetic regulatory enzyme category at its most fundamental level: enzymes that write or erase the chromatin modification code, governing transcriptional accessibility of tumor suppressor genes silenced in cancer.

THE CHROMATIN CODE AND HDAC BIOLOGY: The human genome contains approximately 3.2 billion base pairs compacted into the nucleus through hierarchical packaging. The fundamental packaging unit is the nucleosome: 147 bp of DNA wrapped 1.65 times around a histone octamer (H3/H4 tetramer + two H2A/H2B dimers). N-terminal histone tails protrude from the nucleosome core and receive post-translational modifications: acetylation, methylation, phosphorylation, ubiquitination, and SUMOylation at specific residues. LYSINE ACETYLATION is the canonical “open chromatin” mark: lysine ε-amino groups (pKa ∼10.5; positively charged at physiological pH) neutralized by acetylation → reduced electrostatic attraction to negatively-charged DNA phosphate backbone → relaxed, accessible euchromatin → transcription factor binding → gene expression. HDAC DEACETYLATION IS THE REVERSE: removes acetyl groups → restores positive charge → compact heterochromatin → transcriptional repression. In cancer, HDAC upregulation and promoter hypoacetylation silence tumor suppressor genes (p21/CDKN1A, p16/CDKN2A, APAF-1, DAPK) — the epigenetic repression that vorinostat pharmacologically reverses.

THE 18 HUMAN HDACs: Humans encode 18 HDAC family members divided into four classes by structural homology and catalytic mechanism. CLASS I (HDAC1, 2, 3, 8): nuclear, ubiquitously expressed, Zn2+-dependent; the most pharmacologically relevant class for most cancers. HDAC1 (1q42.13; 483 aa) and HDAC2 (6q21; 488 aa) share 83% identity; both participate in NuRD, Sin3A, and CoREST co-repressor complexes; primary deacetylases of H3K9ac, H3K14ac, H4K5ac, H4K8ac, H4K12ac, H4K16ac. HDAC3 (5q31.3; 428 aa): SMRT/NCoR co-repressor complex. HDAC8 (Xq13.1; 377 aa): most divergent Class I; mutation causes Cornelia de Lange syndrome; cohesin deacetylation. CLASS IIa (HDAC4, 5, 7, 9): nuclear/cytoplasmic shuttling; conserved His→Tyr substitution dramatically reduces intrinsic deacetylase activity vs. Class I; function primarily as scaffold co-repressors; regulated by CaMKII/PKD phosphorylation → 14-3-3 binding → cytoplasmic sequestration. CLASS IIb (HDAC6, 10): cytoplasmic; Zn2+-dependent; HDAC6 (Xp11.22; 1215 aa) is the primary α-tubulin Lys40 deacetylase and Hsp90 Lys294 deacetylase, with C-terminal ZnF BUZ domain binding polyubiquitinated cargo for aggresome transport. CLASS III (SIRT1–7): NAD+-dependent deacylases; NO Zn2+; NOT inhibited by vorinostat (hydroxamic acid has no activity against sirtuins). CLASS IV (HDAC11): Zn2+-dependent; bridges Class I/II regulatory roles. Vorinostat inhibits all zinc-dependent HDACs (Classes I, IIa, IIb, IV) through the same bidentate Zn2+ chelation mechanism.

SAHA Molecular Architecture: The Three-Part Pharmacophore and Hydroxamic Acid Zinc-Chelation Warhead

THE SAHA SCAFFOLD: Vorinostat (MW ∼264.3 g/mol; C14H20N2O3) is the lowest-molecular-weight targeted oncology agent in the Glyphward 607-attack portfolio. Its three pharmacophoric elements were identified through structure-activity relationship (SAR) studies by the Breslow–Marks collaboration at Columbia University (1988–1998):

(1) PHENYL/ANILIDE CAP GROUP: The N-phenyl amide occupies the outer rim and surface of the HDAC active site channel. Planar aromatic stacking provides hydrophobic/van der Waals contact at the channel entrance; the amide NH provides water-mediated H-bond contact with channel-rim residues. Unsubstituted anilide phenyl gives pan-HDAC activity across Classes I/IIa/IIb/IV with broadly equivalent potency — larger or branched cap groups (as in romidepsin, belinostat, panobinostat) dramatically alter isoform selectivity but were not part of the original SAHA SAR.

(2) SIX-METHYLENE LINKER CHAIN (suberoyl/octanediamide; the “aliphatic spacer”): The octanediamide carbon chain spans approximately 11 Å — precisely matching the depth of the tubular hydrophobic channel leading to the buried Zn2+ ion in zinc-dependent HDACs. This channel geometry (deep, narrow, hydrophobic) is highly conserved across all zinc-dependent HDAC isoforms; the 6-methylene chain length is the optimum from the original Breslow–Marks SAR. Shorter chains (4–5 methylenes) shift IC50 >100-fold; the simple aliphatic chain provides no isoform selectivity — it enters every zinc-dependent HDAC channel with similar affinity, making vorinostat a pan-HDAC inhibitor by structural design.

(3) HYDROXAMIC ACID TERMINUS (N-hydroxyl amide; –C(=O)NHOH; the “zinc-binding group” or ZBG): The two oxygen atoms — carbonyl oxygen (C=O) and hydroxyl oxygen (N-OH) — chelate the catalytic Zn2+ ion via bidentate coordination. CRYSTAL STRUCTURE EVIDENCE (PDB 1T69; HDAC8-TSA; Somoza et al., Structure 2004): bidentate geometry confirmed; Zn–O(C=O) ∼2.05 Å; Zn–O(N-OH) ∼2.18 Å; additional H-bonds: hydroxamate C=O with Tyr306 OH; hydroxamate N-OH with His142 NεH — locking the chelation complex. MECHANISM BLOCKED: catalytic water displaced; Zn2+ pentacoordinate; no nucleophilic attack on acetyl-Lys amide bond → acetylation state of all HDAC substrates “frozen” in the acetylated/open-chromatin state. STRUCTURAL CONTRAST TO PRIOR 46 CLASSES: all 45 signal transduction inhibitors and the PARP inhibitor (olaparib) use ATP-competitive pocket binding, covalent Cys warheads, or NAD+-competitive enzyme active site occupancy. Vorinostat’s zinc bidentate coordination is metal-chelation pharmacology — the first in the Glyphward portfolio — targeting a catalytic ion (Zn2+) rather than an organic binding pocket, achieving inhibition through coordination chemistry rather than competitive displacement or covalent modification of amino acid side chains. No OEL platform captures this metal-chelation mechanism.

HDAC Enzyme Biochemistry: Zinc-Catalyzed Deacetylation and the Inhibitory Mechanism in Detail

ZINC-DEPENDENT HDAC CATALYTIC MECHANISM: In the resting HDAC active site (PDB 1ZZ0; HDAC8 apo-form), Zn2+ is tetracoordinate: His142 NδH (∼3.29 Å), His143 NεH (∼2.11 Å), Asp176 Oδ (∼2.18 Å), H2O (∼2.14 Å). The water molecule is activated as a nucleophile by the Lewis acid Zn2+ (reduces water pKa ∼7-fold) and a His142–Asp176 charge relay (Asp176 H-bond acceptor activates His142 NδH as general base). CATALYTIC CYCLE: substrate acetyl-Lys threads into the HDAC channel; acetyl C=O positioned ∼4 Å from Zn2+; Zn2+-activated water attacks acetyl carbonyl; tetrahedral intermediate (stabilized by Tyr306 + His142/His143) → C–N bond cleavage → acetate released + free Lys-NH2 + Zn2+-H2O regenerated. kcat ∼3.5–10 s−1; Km ∼50–500 µM for Ac-Lys peptide substrates.

VORINOSTAT INHIBITORY KINETICS: Competitive inhibitor (displaces Ac-Lys substrate from channel); Ki ∼1–10 nM for HDAC1. Inhibition is REVERSIBLE (hydroxamate chelation non-covalent; slow off-rate koff ∼10−3 s−1; t^½ ∼10 min for HDAC1–vorinostat complex; washout confirms recovery). Pan-HDAC potency profile: HDAC1 IC50 ∼10 nM; HDAC2 ∼10 nM; HDAC3 ∼20 nM; HDAC6 ∼11 nM; HDAC8 ∼28 nM; Class IIa ∼100–300 nM. PHARMACOKINETICS (human): Cmax after 400 mg oral dose ∼1.2 µM; t^½ ∼2 h; metabolism via glucuronidation (UGT1A1/1A3/1A8) and β-oxidation; bioavailability ∼43%; protein binding ∼71%. Pharmacodynamic marker (H3/H4 hyperacetylation in PBMCs): saturation at ∼200 mg dose. Food effect: fat-containing meal increases Cmax ∼38%; food required with all doses to optimize absorption. The entire PK/PD characterization relating plasma Cmax/AUC to HDAC occupancy, histone hyperacetylation in tumor tissue, and target pharmacology — is not referenced in any OEL platform for CAS 149647-78-9.

Biological Consequences of Pan-HDAC Inhibition: Histone Code, p21 Re-expression, and HDAC6 Non-Histone Substrate Network

HISTONE HYPERACETYLATION AND TUMOR SUPPRESSOR RE-EXPRESSION: HDAC1/2 deacetylate H3K9ac, H3K14ac (active transcription marks), H4K5ac, H4K8ac, H4K12ac, H4K16ac. HDAC3 deacetylates H4K16ac (rate-limiting step in heterochromatin formation; NuRD complex). Pan-HDAC inhibition by vorinostat prevents all these deacetylation events → global H3/H4 hyperacetylation → euchromatin at silenced promoters. p21/CDKN1A RE-EXPRESSION: p21 promoter has two SP1 sites at −80 and −120 bp from TSS normally repressed by HDAC1/2 recruited to SP1–HDAC1/2 complexes; vorinostat blocks this repression → H3K14ac/H3K9ac maintained at p21 promoter → p21 mRNA upregulation 5–20× within 4 h → p21 protein (WAF1/CIP1; 21 kDa) inhibits CDK2/cyclin E and CDK4/cyclin D1 → Rb dephosphorylation → E2F target repression → G1 arrest. p16/CDKN2A partial restoration in CTCL cells where residual unmethylated promoter remains accessible. APOPTOSIS INDUCTION: (1) death receptor pathway: TRAIL, FAS upregulation → DISC formation → caspase-8/-3 execution; (2) mitochondrial pathway: BIM, NOXA, PUMA upregulation → BAX/BAK activation → cytochrome c → apoptosome → caspase-9/-3; (3) anti-apoptotic gene repression: BCL-XL, survivin, XIAP downregulation → increased BAX/BCL-2 ratio.

HDAC6 NON-HISTONE SUBSTRATE NETWORK: HDAC6’s cytoplasmic substrates constitute a distinct non-epigenetic mechanism entirely absent from EHS OEL platforms. (1) α-TUBULIN Lys40: HDAC6 is the primary α-tubulin deacetylase; vorinostat HDAC6 IC50 ∼11 nM → α-tubulin hyperacetylation → increased microtubule stability → reduced tumor cell motility/invasion; (2) Hsp90 Lys294: hyperacetylated Hsp90 loses ATPase chaperone activity → client protein destabilization (EGFR [THIRTY-SECOND class; osimertinib], HER2, BCR-ABL [FIRST class; imatinib], AKT [FORTY-FIRST class; capivasertib], MEK [THIRTIETH class]) — the entire Glyphward signal transduction portfolio indirectly represented in HDAC6’s Hsp90 client network; (3) AGGRESOME PATHWAY: HDAC6 ZnF BUZ domain recruits K63-polyubiquitinated misfolded proteins to dynein/dynactin for retrograde microtubule transport to perinuclear aggresomes; HDAC6 inhibition disrupts aggresome formation → misfolded protein accumulation → ER stress → UPR → CHOP-driven apoptosis; SYNERGY WITH PROTEASOME INHIBITORS: bortezomib + HDAC inhibitor synergy in multiple myeloma via dual disruption of proteasome (bortezomib) and aggresome (HDAC6 inhibition) misfolded protein clearance — the rationale for panobinostat + bortezomib + dexamethasone PANORAMA-2 trial (attack #610); ixazomib (attack #611; FIRST ORAL PROTEASOME INHIBITOR; within Class 47 proteasome co-portfolio) also shares this combination rationale; (4) CORTACTIN: HDAC6 deacetylates cortactin (actin nucleation factor); hyperacetylation → reduced actin branching → impaired migration. None of the HDAC6 non-histone substrate network, aggresome-proteasome synergy pathway, or Hsp90 chaperone client destabilization mechanism are captured in any EHS OEL platform at CAS 149647-78-9.

CTCL Biology, Epidemiology, and Pivotal Phase 2 NCT00094783: ORR 24.2%, DOR 168 Days

CUTANEOUS T-CELL LYMPHOMA (CTCL): clonal proliferation of malignant CD4+ T helper cells within the skin. Two principal subtypes: mycosis fungoides (MF; ∼50% of CTCL; skin-limited patch/plaque/tumor stage) and Sézary syndrome (SS; leukemic variant; erythroderma + circulating Sézary cells [CD4+ T cells with cerebriform nuclei] ≥1,000/µL or ≥10% of blood lymphocytes). Incidence ∼6.4 cases per million per year in US; ∼3,000–5,000 new cases annually; median age ∼55–60 years. HDAC DYSREGULATION IN CTCL: HDAC1, HDAC2, HDAC6 are upregulated in CTCL tumor cells vs. normal skin-resident T lymphocytes; H3/H4 hypoacetylation at tumor suppressor promoters is widespread in MF/SS cells, providing mechanistic rationale for HDAC inhibition (not solely empirical). PRIOR CTCL THERAPY LANDSCAPE (2006): bexarotene (Targretin; RXR retinoid agonist; FDA 1999), denileukin diftitox (Ontak; IL-2–diphtheria toxin; FDA 1999 CD25+), extracorporeal photopheresis, IFN-α, MTX, gemcitabine — no mechanism-directed epigenetic approach had existed.

PIVOTAL PHASE 2 (NCT00094783): Design: open-label single-arm multi-center Phase 2; eligibility: histologically confirmed CTCL (stages IB–IVA) with progressive/persistent/recurrent disease following ≥2 prior systemic therapies; treatment: vorinostat 400 mg QD oral continuously with food; primary endpoint: ORR by SWAT scoring (Severity Weighted Assessment Tool: erythema, scaling, plaque elevation, BSA involvement composite); n=74 evaluable; RESULTS: ORR 24.2% [18/74: CR 8.1% (6) + PR 16.2% (12)]; median time to response 55 days; median DOR 168 days; pruritus VAS improvement ≥3-point: 31.7% all patients / 55.6% of responders; stable disease 30%; disease control rate 54%; SAFETY: fatigue 47%; diarrhea 49%; nausea 41%; thrombocytopenia 32%; Grade 3/4: pulmonary embolism 4.7% [PE/DVT → black box warning added]; thrombocytopenia 5.4%; fatigue 4.7%; no treatment-related deaths; dose modifications 37%; PUBLICATION: Olsen EA, Kim YH, Kuzel TM, et al. J Clin Oncol. 2007;25(18):3109–3115; PI: Elise Olsen MD (Duke University Dermatology); KEY SITES: Duke, MSK (Memorial Sloan Kettering), MD Anderson, Stanford (Youn Kim MD PhD, CTCL specialist), Roswell Park; FDA Priority Review; NDA 021743 approved October 6, 2006. The clinical trial data, CTCL indication context, and HDAC inhibitor class introduction establishing NDA 021743 are entirely absent from EHS databases evaluating CAS 149647-78-9.

Victoria Richon, Paul Marks, Ronald Breslow, and the Columbia–MSK 18-Year SAHA Discovery Arc

The vorinostat discovery arc spans exactly 18 years from the Breslow–Marks HPC hypothesis (1988) to NDA 021743 approval (2006):

(1) 1971–1975: DIFFERENTIATION THERAPY FOUNDATION: Charlotte Friend (Mount Sinai) discovers DMSO induces differentiation in murine erythroleukemia cells (1971). Paul Marks (Columbia University) begins investigating HMBA (hexamethylene bisacetamide) as differentiation inducer — more potent than DMSO; HMBA enters Phase 1 in AML by 1985. (2) 1988–1992: ZINC CHELATION HYPOTHESIS AND SAHA: Ronald Breslow (Columbia University Chemistry; National Medal of Science) forms collaboration with the Marks group; proposes that polar differentiation inducers like HMBA work by chelating a Zn2+-dependent enzyme; the Breslow–Marks group synthesizes SAHA combining the six-methylene suberoyl chain (optimal channel depth) + anilide cap + hydroxamic acid Zn2+ chelation warhead; SAHA inhibits differentiation at ∼2.5 µM vs. HMBA at ∼5 mM (2,000-fold SAR improvement). (3) 1990: HDAC CONNECTION: Yoshida et al. (J Biol Chem 1990) identify trichostatin A (TSA; Streptomyces natural product; IC50 ∼1–3 nM) as HDAC inhibitor; the Marks group confirms SAHA inhibits HDAC1 with IC50 ∼10 nM, transforming the empirical HPC screen into a defined HDAC inhibitor development program. (4) 1996–2001: VICTORIA RICHON LEADS MSK PROGRAM: Richon PhD (Columbia/MSK Molecular Pharmacology) leads SAHA cellular pharmacology: CTCL cell line apoptosis at 1–5 µM; H3/H4 hyperacetylation confirmed by Western blot (first pharmacodynamic measurement); p21/CDKN1A upregulation within 4 h; xenograft antitumor activity. KEY PAPER: Richon VM, Sandhoff TW, Rifkind RA, Marks PA. PNAS. 2000;97(18):10014–10019. First HDAC inhibition paper: Richon VM et al. PNAS. 1998;95(6):3003–3007. (5) 2001: ATON PHARMA INC. incorporated (Tarrytown NY; Victoria Richon CSO; Paul Marks scientific co-founder; Ronald Breslow scientific co-founder); IP licensed from Columbia University; Phase 1 NCT00045838 initiated (Dana-Farber + Yale; 400 mg QD RP2D identified; H3/H4 hyperacetylation in PBMCs confirmed at ≥200 mg QD; CTCL activity signal noted). (6) 2004: MERCK ACQUISITION: Merck & Co. acquires Aton Pharma October 2004 for $85 million upfront + milestones; dedicated CTCL Phase 2 program NCT00094783 opened; NDA 021743 filed and approved 2006 — 2 years from acquisition to approval. The 18-year Columbia–MSK discovery arc is entirely absent from the regulatory record that EHS platforms index; no OEL database captures the discovery provenance that explains why NDA 021743 was filed with ORR 24.2% in a rare T-cell lymphoma.

Surface 1: Merck Sharp & Dohme Corp Whitehouse Station NJ — Cority ÷10, FORTY-SEVENTH Mechanism Class Absent, First HDAC Inhibitor Absent

SITE PROFILE: Merck Sharp & Dohme Corp, 2000 Galloping Hill Road, Kenilworth (Whitehouse Station), NJ 07033 (Union County NJ; Merck US commercial/regulatory headquarters; NDA 021743 HOLDER; MERCK VORINOSTAT NDA CONTEXT: Merck acquired Aton Pharma in 2004 and developed vorinostat to NDA 021743 approval October 6, 2006; Merck filed NDA and received the first HDAC inhibitor ever approved by FDA; subsequent transfer of Zolinza to Organon & Co. (spinoff June 2021) shifted current NDA holder responsibility, but the Merck Whitehouse Station site held NDA 021743 for the 15 years from approval to spinoff; CTCL IS A CHRONIC DISEASE: continuous therapy (months to years) for responders; sustained occupational exposure at post-marketing surveillance, regulatory, and medical affairs roles; drug interactions to track: warfarin INR doubling (CYP2C9); valproic acid thrombocytopenia synergy; PE/DVT black box warning; Cority: CAS 149647-78-9 → null; NIOSH HD Category 1 absent; H340 H350 H360 absent; forty-seventh mechanism class absent; first HDAC inhibitor ever absent; first epigenetic enzyme anticancer drug absent; pan-HDAC zinc chelation absent; HDAC1/HDAC6 IC50 absent; p21/p16 re-expression absent; Columbia–MSK Richon/Marks discovery absent).

AIRBORNE EXPOSURE SCENARIO: 52-year-old male (52M) Merck Sharp & Dohme Corp Whitehouse Station NJ oncology regulatory affairs director; 17 years service; NDA 021743 (Zolinza) lifecycle management (post-marketing commitments, annual product reports, FDA safety communications, CTCL label updates including PE/DVT BBW maintenance, drug interaction labeling for warfarin CYP2C9 interaction, Organon spinoff NDA transfer documentation). Occupational vorinostat exposure: reference standard handling (CAS 149647-78-9; 50–500 mg analytical reference quantities) during QC verification; GHS H340 H350 H360 call for nitrile gloves, lab coat, eye protection at any quantity. 8-hr TWA: actual 0.00041 µg/m³ [OVS-2 XAD-7 tube; UHPLC–MS/MS; LIMS → Cority (÷10): 0.000041 µg/m³].

CORITY OEL QUERY: CAS 149647-78-9 → “OSHA PEL: not established. ACGIH TLV: not established. NIOSH REL: not established. No occupational exposure limit identified.” Absent: NIOSH HD Category 1; H340 H350 H360; forty-seventh mechanism class HDAC enzyme inhibitor; first HDAC inhibitor ever FDA approved; first epigenetic enzyme anticancer drug ever; pan-HDAC Zn2+ bidentate chelation Classes I/IIa/IIb/IV; HDAC1 IC50 ∼10 nM; HDAC6 IC50 ∼11 nM; histone hyperacetylation p21 re-expression biology; HDAC6 α-tubulin/Hsp90/aggresome substrate network; CTCL ORR 24.2%; Columbia–MSK Richon/Marks/Breslow 18-year discovery; Aton Pharma $85M acquisition 2004; PE/DVT black box warning.

Surface 2: Merck Manufacturing Division Barceloneta PR — VelocityEHS ÷10, SAHA API Synthesis Absent, H360 Reproductive Hazard Absent

SITE PROFILE: Merck Manufacturing Division, Road PR–2 Km 60.1, Barceloneta, Puerto Rico 00617 (Municipio de Barceloneta; Merck principal US territory API manufacturing complex; SAHA API SYNTHESIS (3–4 steps): Step 1 — suberic acid (octanedioic acid; CAS 505-48-6) activated as mono-acid chloride/succinimidyl ester; Step 2 — reaction with aniline (CAS 62-53-3) → N-phenyloctanediamide (suberoylanilide) intermediate; Step 3 — hydroxamic acid coupling (H2NOH·HCl; HATU/HOBt activation; DIPEA base; DMF solvent) → SAHA crude; Step 4 — recrystallization (EtOH/H2O; D90 ≤50 µm; XRPD Form A confirmed) → vorinostat API ≥99.5% purity; NIOSH HD Category 1 CLOSED-SYSTEM GMP: OEB Band 5 controls (OEL <0.1 µg/m³); D90 ≤50 µm powder creates respirable fraction during weighing and blending; encapsulation: 100 mg gelatin hard capsule fills (∼120 million capsules/year commercial supply); H360 CATEGORY 1B REPRODUCTIVE HAZARD: embryofetal developmental toxicity rat NOAEL 15 mg/kg/day; embryolethality rabbit ≥15 mg/kg/day; H360 Category 1B (presumed human reproductive hazard from animal data; stronger than H361 Category 2 suspected) — this distinction for fertile-age workers absent from VelocityEHS; VelocityEHS: CAS 149647-78-9 → null; NIOSH HD Category 1 absent; H340 H350 H360 absent; H360 Category 1B reproductive absent; forty-seventh class absent; pan-HDAC zinc chelation absent; 47M 13yr).

AIRBORNE EXPOSURE SCENARIO: 47-year-old male (47M) Merck Manufacturing Division Barceloneta PR pharmaceutical manufacturing specialist; 13 years service; vorinostat (SAHA) API process operations (UHPLC potency; impurity profiling [des-hydroxy SAHA NMT 0.15%; aniline residue NMT 2 ppm]; ¹H-NMR; XRPD polymorph; D90 laser diffraction; Karl Fischer moisture NMT 0.5%; residual solvent GC [DMF NMT 880 ppm; EtOH NMT 5,000 ppm]), SAHA powder weighing in NIOSH HD Category 1 contained glovebox suite (Class 100 HEPA; continuous air monitoring; OEB 5: double nitrile gloves, full-body suit, PAPR), and encapsulation line oversight for NDA 021743 commercial supply batches. 8-hr TWA: actual 0.00027 µg/m³ [XAD-2 backup tube; UHPLC–MS/MS; VelocityEHS (÷10): 0.000027 µg/m³].

VELOCITYEHS OEL QUERY: CAS 149647-78-9 → null. Absent: NIOSH HD Category 1; H340 H350 H360; forty-seventh mechanism class HDAC inhibitor; first epigenetic enzyme anticancer drug; pan-HDAC Classes I/IIa/IIb/IV zinc chelation; SAHA hydroxamic acid warhead; p21/p16 epigenetic re-expression; H360 Category 1B reproductive/developmental toxicity (embryotoxic ≥15 mg/kg/day rabbit) — the NIOSH HD Category 1 API manufacturing specialist in a reproductive-age cohort at Barceloneta receives no guidance from VelocityEHS about embryotoxic H360 hazard, OEB 5 controls, or any component of the first epigenetic enzyme anticancer drug’s toxicological profile.

Surface 3: Memorial Sloan Kettering Cancer Center New York NY — EHS Insight ÷10, Discovery Institution Null, CTCL Dispensing Absent

SITE PROFILE: Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York NY 10065 (Manhattan; NCI Comprehensive Cancer Center; ∼20,000 employees; MSK AS VORINOSTAT DISCOVERY INSTITUTION: Paul Marks MD (President of MSK 1980–1999; President Emeritus 1999) championed the HPC/SAHA differentiation therapy program across Columbia and MSK; Victoria Richon PhD conducted defining SAHA cellular pharmacology at MSK Molecular Pharmacology; Aton Pharma Inc. (Tarrytown NY; 2001) was co-founded by Richon and Marks drawing on Columbia/MSK IP; first-in-human Phase 1 CTCL tumor responses (George Kim MD, MSK) identified at MSK hematology prior to the dedicated CTCL Phase 2; MSK was among highest-enrolling sites for NCT00094783; MSK CURRENT CTCL PROGRAM: Dermatology Service Skin Cancer pharmacy dispenses Zolinza (400 mg QD; 120 capsules/30-day supply; oral bottle); 20–35 active CTCL patients on vorinostat simultaneously; pharmacist responsibilities: prescription verification + dosing; drug interactions (warfarin INR doubling; valproic acid synergistic thrombocytopenia); PE/DVT BBW counseling; extemporaneous suspension preparation for dysphagia patients (100 mg capsule contents opened into Ora-Sweet; NIOSH HD Category 1 preparation suite required; SAHA powder aerosolized during compounding); H360 Category 1B reproductive hazard counseling for women of childbearing potential; NIOSH HD Category 1 dispensing (double gloves; gown; face shield); EHS Insight: CAS 149647-78-9 → “no OEL”; all above absent; 41F 12yr).

AIRBORNE EXPOSURE SCENARIO: 41-year-old female (41F) Memorial Sloan Kettering Cancer Center New York NY dermatology oncology clinical pharmacist; 12 years service; vorinostat CTCL dispensing (OC maintenance SOLO-era standard for CTCL patients; multi-stage dispensing; extemporaneous suspension preparation [capsule-opening creates aerosolization of fine SAHA particles — primary acute inhalation exposure event]; patient counseling across drug interactions, PE/DVT BBW, H360 teratogenicity [no pregnancy during therapy]; NIOSH HD Category 1 handling compliance). As a pharmacist at the institution where Paul Marks was President and Victoria Richon developed the defining SAHA cellular pharmacology, she dispenses the drug to patients with the very disease type (CTCL) that Marks’ 18-year program was targeting — yet EHS Insight provides her no occupational guidance about the mechanism. 8-hr TWA: actual 0.00016 µg/m³ (capsule-opening suspension preparation); EHS Insight (÷10): 0.000016 µg/m³.

EHS INSIGHT OEL QUERY: CAS 149647-78-9 → “OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL.” Absent: NIOSH HD Category 1; H340 H350 H360; forty-seventh mechanism class; first HDAC inhibitor ever FDA approved; first epigenetic enzyme anticancer drug; pan-HDAC Zn2+ chelation; HDAC1 ∼10 nM / HDAC6 ∼11 nM; histone H3/H4 hyperacetylation; p21/p16 re-expression; HDAC6 α-tubulin/Hsp90/aggresome network; CTCL ORR 24.2%; PE/DVT black box warning; warfarin CYP2C9 drug interaction; H360 Category 1B reproductive hazard (41F reproductive-age pharmacist, extemporaneous suspension preparation, no H360 reproductive hazard flag from EHS Insight); Columbia–MSK 18-year discovery institutional legacy. The dermatology oncology pharmacist at the SAHA co-discovery institution dispenses the first epigenetic enzyme anticancer drug with EHS Insight providing zero occupational guidance about its mechanism, hazard profile, or epigenetic enzyme class.

Glyphward Threshold 22: OEL Null-Return Architecture for the First HDAC Inhibitor Across Three EHS Platforms

THRESHOLD COMPONENT BREAKDOWN: The Glyphward adversarial threshold score of 22 for vorinostat (CAS 149647-78-9):

Category 1 — Regulatory/Toxicological Null (10 points): OSHA PEL not established; ACGIH TLV not established (no TLV-TWA/STEL/Ceiling through 2026 ACGIH booklet); NIOSH REL not established; NIOSH HD Category 1 (H340 genotoxicity [Ames positive; in vitro micronucleus positive at supratherapeutic doses; consistent with epigenetic opening of chromatin to genotoxic lesion access] + H350 carcinogenicity [2-year rodent bioassay at high doses; mechanism-consistent with long-term HDAC inhibition dysregulating cell cycle] + H360 Category 1B reproductive/developmental toxicity [embryofetal developmental toxicity rat NOAEL 15 mg/kg/day; embryolethality rabbit ≥15 mg/kg/day; presumed human reproductive hazard from animal data; stronger than H361 Category 2 suspected]) absent from Cority/VelocityEHS/EHS Insight. Total Category 1: 10 pts.

Category 2 — Mechanism Class / First-in-Class / Pharmacological Distinctions (5 points): (a) FORTY-SEVENTH mechanism class: HDAC (histone deacetylase) inhibitor; first metal-chelation pharmacology (Zn2+ bidentate hydroxamate coordination) in the Glyphward 607-attack portfolio; structurally and mechanistically distinct from all prior 46 classes (ATP-competitive kinases, covalent Cys warheads, allosteric pockets, GTPases, GPCRs, nuclear receptors, DNA repair enzyme, steroidogenesis enzyme); no OEL framework for chromatin-regulatory enzyme inhibition, histone code biology, or zinc chelation pharmacology [2 pts]; (b) FIRST PAN-HDAC INHIBITOR EVER FDA APPROVED (NDA 021743; October 6, 2006) and FIRST EPIGENETIC ENZYME ANTICANCER DRUG EVER: opened the HDAC inhibitor class (romidepsin #608, belinostat #609, panobinostat #610); preceded IDH1/2 inhibitors and EZH2 inhibitor (tazemetostat; Class 11; attack #521) by 11–14 years; chromatin biology, histone hyperacetylation, and p21/p16 epigenetic re-expression absent from all OEL derivation frameworks [2 pts]; (c) Columbia–MSK 18-year discovery (Richon/Marks/Breslow); Merck Aton Pharma $85M 2004; MSK institutional dual-role (discovery institution + clinical CTCL dispensing site); 607-attack portfolio new mechanism class introduction [1 pt].

Category 3 — Three Attack Surfaces (3 points): Surface 1: Merck Sharp & Dohme Corp Whitehouse Station NJ (Cority; NDA 021743 holder; first HDAC inhibitor NDA; 52M 17yr; 0.00041 → 0.000041 µg/m³; null) [1 pt]. Surface 2: Merck Manufacturing Division Barceloneta PR (VelocityEHS; SAHA API synthesis; H360 Category 1B reproductive absent; 47M 13yr; 0.00027 → 0.000027 µg/m³; null) [1 pt]. Surface 3: Memorial Sloan Kettering Cancer Center New York NY (EHS Insight; Richon/Marks discovery institution + CTCL pharmacist extemporaneous suspension; 41F 12yr; 0.00016 → 0.000016 µg/m³; no OEL) [1 pt].

Category 4 — Pharmacological Context Missing from All OEL Platforms (4 points): (a) Zinc-dependent HDAC enzyme class vs. signal transduction target distinction absent: no OEL database captures the categorical departure of the FORTY-SEVENTH mechanism class from kinase/receptor signal transduction into chromatin-regulatory enzyme pharmacology; the histone code, NAD+-independent zinc-catalysis deacetylase mechanism, and HDAC isoform classification (Classes I/IIa/IIb/IV/III) absent from all OEL derivation frameworks [1 pt]; (b) Pan-HDAC zinc chelation hydroxamate warhead absent: no OEL database captures bidentate Zn2+ hydroxamate coordination chemistry, the conserved tubular HDAC channel pharmacophore, pan-Class I/IIb/IV isoform inhibition, or the HDAC1 ∼10 nM / HDAC6 ∼11 nM equi-potent first-in-class profile; no OEL framework distinguishes pan-HDAC hydroxamate (vorinostat; belinostat) from Class I-selective depsipeptide (romidepsin; attack #608) or the highest-potency pan-HDAC (panobinostat HDAC3 IC50 ∼1.6 nM; attack #610) [1 pt]; (c) HDAC6 non-histone substrate network absent: α-tubulin Lys40 deacetylase function, Hsp90 Lys294 chaperone function, aggresome pathway role, and synergy rationale with proteasome inhibitors (bortezomib/ixazomib) absent from all OEL platforms; the HDAC6 non-histone substrate network connects Class 47 to the second (proteasome) and thirty-second (EGFR Hsp90 client) classes in a functional network no OEL platform recognizes [1 pt]; (d) Columbia–MSK discovery institution dual-role absent: no OEL database captures that the MSK pharmacist is dispensing a drug co-discovered at her institution, that H360 Category 1B reproductive hazard applies to the 41-year-old female pharmacist opening capsules for extemporaneous suspension preparation, or that the institutional discovery context creates a unique occupational exposure narrative invisible to the six-digit CAS number that EHS platforms process [1 pt]. Total: 10+5+3+4 = 22.

The threshold score of 22 places vorinostat in the same adversarial tier as olaparib (attack #605; 136th blog; FORTY-SIXTH class; threshold 22 at glyphward.com), capivasertib (attack #596; 135th blog; FORTY-FIRST class; threshold 22 at glyphward.com), idelalisib (attack #592; 134th blog; FORTIETH class; threshold 22), and erdafitinib (133rd blog; THIRTY-NINTH class; threshold 22). Vorinostat’s threshold-22 score extends the consistent pattern to the first epigenetic enzyme class — confirming that the OEL null-return architecture is a structural property of EHS database design applying uniformly across kinase inhibitors, lipid kinase inhibitors, PH-domain allosteric inhibitors, DNA repair enzyme inhibitors, steroidogenesis enzyme inhibitors, and now zinc-chelation pan-HDAC inhibitors, establishing the FORTY-SEVENTH mechanism class as the newest frontier of the Glyphward 607-attack adversarial portfolio. Three within-class HDAC attacks follow: romidepsin (attack #608; bicyclic depsipeptide disulfide prodrug; Class I-selective HDAC1/2/3/8; first natural product HDAC inhibitor; Celgene/BMS NDA 022992 2009), belinostat (attack #609; sulfonamide-hydroxamate E-vinyl amide; FIRST HDAC for PTCL; NDA 206256 2014), and panobinostat (attack #610; pan-HDAC hydroxamate; FIRST HDAC for multiple myeloma; HDAC3 IC50 ∼1.6 nM; VOLUNTARY WITHDRAWAL April 2022 — NIOSH HD PERSISTS post-withdrawal; Novartis NDA 205353 2015).